Skip to main content
. Author manuscript; available in PMC: 2017 Nov 15.
Published in final edited form as: Cancer. 2016 Aug 10;122(21):3336–3343. doi: 10.1002/cncr.30197

Table 4.

Treatment discontinuation

Dasatinib (N = 87) Nilotinib (N = 87)
Treatment discontinuation, N(%) 18 (21) 20 (23)
Reason for discontinuation, N (% among discontinued patients)
Toxicity 4 (22) 6 (30)
Toxicity and resistance 2 (11) 0 (0)
Resistance/Progression 6 (33) 5 (25)
Death 0 (0) 1 (5)
Financial 1 (6) 4 (20)
Patient choice 3 (17) 1 (5)
Non-adherence 2 (11) 3 (15)